Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva
A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.
You may also be interested in...
The kappa opioid receptor agonist is not listed as a scheduled substance and labeling meets expectations. Cara and partner Vifor plan to launch the product in early 2022.
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.